Protocol ALD403-CLIN-[ADDRESS_385823] ALD403 
Indication Treatment for the Prevention of Chronic Migraine 
Sponsor Alder BioPharmaceuticals, Inc.
[ZIP_CODE] North Creek Pkwy S
Bothell, WA [ZIP_CODE] [LOCATION_003]Phone: [PHONE_6570]Fax: +[PHONE_3688]
Sponsor‚Äôs Medical Monitor
Alder BioPharmaceuticals, Inc.Phone: 
Clinical Trial Compliance Thi s clinical trial will be c onducted in accordance with 
standards of Good Clinical Pr actice, as defined by [CONTACT_313400].
Protocol Date (original)Amendment 1 Date24 October 2016 25 January 2017
Amendment 2 DateAmendment 3 Date16 June 201720 November 201716 January 2018 (Administrative Changes Only)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 3of 78DECLARATION OF THE PR INCIPAL INVESTIGATOR
Title: An Open Label Phase [ADDRESS_385824], with moral 
ethical and scientific principles governing clinical research, and in accordance with Good 
Clinical Practice and applicable federal and local regulations.
Principal Investigator 
_____________________________________ ______________________
Signature [CONTACT_1782]
_____________________________________
Name (printed)
_____________________________________
Title
_____________________________________
Institution
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 4of 781. PROTOCOL SYNOPSIS
Title An Open Label Phase 3 Trial to  Evaluate the Safety of ALD403 
Administered Intravenously in Patients with Chronic Migraine 
Sponsor Alder BioPharmaceuticals, Inc. (Alder)
Investigational Product ALD403, a humanized anti-(calcitonin gene-related peptide) 
(CGRP) monoclonal antibody
Safety Objective To evaluate the long te rm safety of repeat doses of ALD403 
administered intravenously (IV) in chronic migraine (CM) 
patients.
Immunogenicity and Patient Reported OutcomesTo evaluate the pharmacokinetics (PK) and immunogenicity of repeat doses of ALD403 administere d IV to patients with chronic 
migraine.To further evaluate the impact  of ALD403 on various patient 
reported outcomes.
Methodology This is an open label trial in which 120 eligible subjects will 
receive infusions of ALD403.  The trial will include two 
treatment phases.  The primar y treatment phase will include 4
ALD403 infusions 12 weeks apart.  The secondary treatment phase will include 4 additional ALD403 infusions 12 weeks
apart.
In the primary treatment phase, visits will occur on Day 0, Weeks 
2, 4, 8, 12, 24, and 36 and subjects will receive 4 IV infusions of ALD403 on Days 0, Weeks 12, 24, and 36.
Subjects who receive all 4 infusions of ALD403 in the primary 
treatment phase may enter the secondary treatment phase. In the secondary treatment phase, su bjects will receive up to 4 
additional IV infusions of ALD403 for a total of 8 infusions. 
Visits and ALD403 IV infusions will occur on Weeks 48, 60, 72, 
and 84. Subjects will be followe d for 20 weeks until Week 104 
for a total study duration of approximately 106 weeks, including the screening period. 
Subjects who don‚Äôt receive all 4 infusions of ALD403 in the 
primary treatment phase or don‚Äôt c onsent for participation in the 
secondary treatment phase will be followed at Week [ADDRESS_385825] Selection Criteria Males  and females between 18 and 65 years of age, inclusive, 
ZKRZHUHGLDJQRVHGZLWKPLJUDLQHVDW¬î\HDUVRIDJHDQG
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 5of 78KDYHDKLVWRU\RIFKURQLFPLJ UDLQHIRU¬ïPRQWKVEHIRUH
screening.  
Investigational Product, 
Dose and ScheduleEight intravenous infusions of 300mg ALD403 will be given 12 weeks apart.  Infusions will occur on Day 0, Week 12 (Day 84 +/- 3 days); Week 24 (Day 168 +/- 3 days); Week 36 (Day 252 +/- 3 days); Week 48 (Day 336 -7/+14 days); Week 60 (Day 420 +/- 7 days); Week 72 (Day 504 +/- 7 days); and Week 84 (Day 588 +/- 7 days).
Duration of Treatment Up to 8 IV infusions of ALD403 will be given approximately 12 
weeks apart over an 84 week period. 
Duration of Clinical Trial ParticipationThe trial participation period is approximately 106 weeks which includes:
x2-week screening period,
x48-week primary treatment administration period,
x36-week secondary treatme nt administration period
x20-week follow-up period.
Clinical Trial Endpoints Safety Endpoints
xAdverse events (AEs) and serious adverse events (SAEs)
xClinical laboratory assessments 
xVital Signs
xElectrocardiograms (ECGs)
xColumbia-Suicide Severity Rating Scale (C-SSRS)
Patient Reported Outcomes
xPatient Global Impression of Change (PGIC) 
xShort-Form Health Survey (SF-36)
xHealth-Related Quality of Life (EQ-5D-5L)
xHeadache Impact Test (HIT-6)
xMost Bothersome Symptom (MBS)
xMigraine Disability Assessment (MIDAS)
PK and Immunogenicity EndpointsxFree ALD403 plasma concentrations
xDevelopment of specific anti-ALD403 antibodies
xCharacterization of specifi c anti-ALD403 antibodies for 
neutralizing activity
Concomitant Medications xSubjects on stable medication for headache prophylaxis for 
[ADDRESS_385826]‚Äôs primary treating 
healthcare professional.
xBarbiturates and prescription opi[INVESTIGATOR_169003] 
¬î[ADDRESS_385827] has been on a stable 
UHJLPHQ¬îGD\VSHUPRQWKIRU DWOHDVWPRQWKVSULRUWR
screening and through entire study. After enrollment, the use of prescription barbiturates and opi[INVESTIGATOR_313379] a licensed healthcare professional for indications other than migraine. 
xBotulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck are prohibited 4 months prior to screening and through entire study.
xDevices, neuromodulation, neur ostimulation, or injectable 
therapy (trigger point injections) for headache prophylaxis are prohibited 2 months prior to screening and through entire study.
xAny use of monoamine oxidase inhibitors (MAOIs), 
ketamine, methysergide, methylergonovine, or nimesulide 
within 3 months prior to screening and throughout the entire trial is prohibited.
Sample Size The planned sample size for the study is 120 treated subjects.  It 
is assumed that over 75% of these subjects will complete the primary treatment phase resulting in at least [ADDRESS_385828] result prior to treatment. Testing of these change from baseline results for the SF-36, MIDAS and HIT-6 will be performed.
PK and Immunogenicity AnalysesThe concentrations of ALD403 will be measured in plasma from all ALD403 treated subjects using a validated assay method. 
The PK analysis of plasma will include determination of the 
ALD403 concentrations at Day 0 (pre-dose), immediately post-dose (within 15 minutes of end of infusion), and Weeks 2, 4, 8, 12 (pre-dose), 24 (pre-dose), 36 (pre-dose), 48 (pre-dose), 72 (pre-dose), and 104 End of Trial/Early Withdrawal. 
Population PK analysis will be performed on the results for ALD403 concentrations obtained during this study in combination with the results from other studies of ALD403 in normal subjects and migraine patients.Blood samples will be collected for the detection of anti-ALD403 antibody, and when appropriate the samples will be analyzed also for neutralizing anti-ALD403 antibody activity at Day 0 (pre-
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 7of 78dose), and on Weeks 2, 4, 8, 12 (pre-dose), 24 (pre-dose), 
36 (pre-dose), 48 (pre-dose), 72 (pre-dose), and 104 End of Trial/Early Withdrawal. Subjects who test positive for specific anti-ALD403 antibodies at the time of  the last study visit will be 
asked to provide up to two additional blood samples for 
immunogenicity testing at approxima tely 3 month intervals for up 
to 6 months. 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 8of 782. SCHEDULE OF EVENTS 
Assessments Screening
Day
-14 to -11Day 0
Treat
ment 
Day 0Wk 2
Day 14
r3 
daysWk 4
Day 28
r3 daysWk 8
Day 56
r3 daysWk 12
Treatmen
t
Day 84
r3 daysWk 24
Treatme
nt 
Day 168
r3 
daysWk 36
Treatme
nt 
Day 252
r3 daysWk 48
Treatment
Day 336  -
7/+ 14 days Wk 60
Treatmen
t
Day 420
r7 daysWk 72
Treatmen
t
Day 504 
r7 daysWk 84
Treatment
Day 588
r7 daysWk 569or 104 
End of Trial / 
Early Withdrawal
Day 392 or 728
¬± 7 days
Informed Consent X
In/Ex Criteria XX
Demographics X
Medical History X
Height X
Weight XX XX X X
Physical Exam1XX XX X X11X X X X
Vital Signs3X X X X X X X X X X
C-SSRS4,1XX X X X X X X X X X X X
Patient Global Impression of 
Change (PGIC)2X X X X X X X X X X
SF-36, HIT-61X X X XX X X X X X X
EQ-5D-5L12X X X XX X X X10
Most Bothersome Symptom 
(MBS)X X X X X X X X X10
MIDAS1X XX X X X X X X
AE Review XX X X XXX X X X X X X
Concomitant Meds Review XX X X XXX X X X X X X
ALD403 infusion5X XX X X11XX X
12-lead ECG7X X X X XX X XX X
Hematology, Chemistry1X X XX XX X XX X
HIV/Hepatitis B and C X
Plasma PK6,8X X X X X X XX X X
Serum Anti-ALD4036X X X X X X XX X X
Urine Drugs of Abuse Screen X
Urine Pregnancy (hCG) Test1XX XX X XX X X X X X
[ADDRESS_385829] assessments pre-dose and up to 2 hours (+ 30 min) post-dose on Day [ADDRESS_385830] C-SSRS Baseline/Screening Version at  screening and C-SSRS Since Last Visit Version at remaining visits where C-SSRS req uired.
5Monitor subjects for at least [ADDRESS_385831] assessment pre-dose, and within 2 hours (+30 min) pos t dose on Day [ADDRESS_385832]-dose (within 15 minutes of end of infusion).
9Subjects who don‚Äôt receive all 4 infusions of ALD403 in the primary treatment phase or don‚Äôt consent to participate in the secon dary treatment phase will have the End of Trial/Early Withdrawal visit at Week 56.  
10Only for subjects who have the End of Trial/Early Withdrawal visit at Week 56.
11Only for subjects who participate in secondary treatment phase.
12Conduct assessment pre-dose on Day [ADDRESS_385833]
IB Investigator‚Äôs Brochure
ICD International Classi fication of Diseases
ICF Informed Consent Form
ICH International Conference on Harmonization
ICHD International Classification of Headache Disorders
IHS International Headache Society
IgG1 Immunoglobulin G1
IP Investigational Product
IRB Institutional Review BoardIV Intravenous
Kg Kilogram
LLOQ Lower Limit of Quantification
M Molarity
m2 Meter squared
mAb Monoclonal antibody
Protocol ALD403-CLIN-[ADDRESS_385834] ...............................................................................................17
5.3.1 Summary of Nonclinical Studies................................................................................175.3.2 Summary of Clinical Trials ........................................................................................195.3.3 Dose Justification........................................................................................................20
5.4        Risks and Benefits ......................................................................................................20
5.5        Compliance Statement................................................................................................21
6 OBJECTIVES.............................................................................................................22
6.1        Safety Objective.......................................................................................................   22
6.2        Immunogenicity and Patient Reported Outcomes ......................................................22
7 TRIAL DESIGN.........................................................................................................23
7.1        Clinical Trial Endpoints..............................................................................................23
7.1.1 Safety Endpoints.........................................................................................................2 3
7.1.2 Patient Reported Outcomes: .......................................................................................237.1.3 PK and Immunogenicity Endpoints:...........................................................................[ADDRESS_385835] Disposition, Demographics, and Baseline Characteristics ............................52
13.4.2 Efficacy Analyses .......................................................................................................5 2
13.4.3 Pharmacokinetic Analyses..........................................................................................5213.4.4 Safety Analyses .......................................................................................................... 53
14 ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS .....................................55
14.1        Data Quality Assurance ..............................................................................................55
14.2        Case Report Forms and Source Documents ...............................................................55
14.2.1 Study Documentation .................................................................................................5514.2.2 Case Report Form.......................................................................................................55
14.3        Archiving Clinical Trial Records................................................................................56
14.4        Good Clinical Practice................................................................................................57
14.5        Informed Consent .......................................................................................................57
14.6        Protocol Approval and Amendment ...........................................................................57
14.6.1 Premature Termination of the Clinical Trial ..............................................................58
14.7              Confidentiality ............................................................................................................58
14.8        Publication Policy.......................................................................................................59
15 APPENDICES ............................................................................................................60
15.1        Migraine preventive therapi[INVESTIGATOR_313380] 13, 14, 15.............60
15.2        Columbia-Suicide Severity Rating Scale (C-SSRS) Risk Assessment ......................61
15.2.1 Baseline/Screening Version........................................................................................6115.2.[ADDRESS_385836] (HIT-6 v1.0)...........................................................................67
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 14of 7815.4        Short-Form Health Survey (SF-36 v2.0) ....................................................................68
15.5        H ealth Related Quality of Life (EQ-5D-5L) ..............................................................72
15.6        Patient Global Impression of Change (PGIC) ............................................................[ADDRESS_385837] Bothersome Symptom (MBS) ...........................................................................76
15.8        The Migraine Disability Assessment (MIDAS) .........................................................[ADDRESS_385838]
ALD403 is a humanized anti-(calcitonin gene-r elated peptide) (CGRP) monoclonal antibody 
(anti-CGRP) that is being developed by [CONTACT_313401]. 
5.2. Background
Migraine is a highly prevalent paroxysmal neurological disease characterized by [CONTACT_313402][INVESTIGATOR_313381], gastrointestinal, and sensory function.  Epi[INVESTIGATOR_313382] [ADDRESS_385839] prevalent through the 
3
rdand 4thdecades of life with a significant gender bias of 3:[ADDRESS_385840] work time and diminished productivity 
attributable to migraine costs Amer ican employers an estimated $19.[ADDRESS_385841] a sign ificant genetic/epi[INVESTIGATOR_313383], races, and ethnicities.  Generally, mi graine begins as an epi[INVESTIGATOR_162122].  Between epi[INVESTIGATOR_313384] a normal (premorbid) state of function.  However, approx imately 2.5% of people with epi[INVESTIGATOR_313385], mean ing they are experiencing migraine on greater 
than [ADDRESS_385842] 3 consecutive months.
4For those with chronic migraine, the 
headaches are more intense; migraine-associated symptoms, more severe; and the disease-related impact and disability are much greater than observed for epi[INVESTIGATOR_17730].
5In addition, chronic 
migraine is associated with more co-morbid diseases such as anxiety, depression, and non-
headache pain.6
The pathophysiology of migraine is complex and incompletely understood.  Current models of 
migraine are based on a genetically determined hy per-excitable nervous system characterized by 
a lowered threshold to sensory activation and uniqueness in its sensory processing.7Interactions 
between this migraine nervous system and speci fic internal and external stimuli (migraine 
triggers) can result in activation of the trigemin ovascular system (TVS).  Once activated the TVS 
releases various vasoactive pep tides generating peripheral sensitiz ation of trigeminal and upper 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 16of 78cervical nociceptors. The ensuing peripheral nociceptive stimuli synapse in the Trigeminal 
Nucleus Caudalis to ultimately create a state of central sensitization.8Clinically, this process is 
observed as a fully develope d attack of migraine.  
Central to this model of migraine is calcitonin gene-related peptide (CGRP) . CGRP is one of the 
most abundant peptides in the human body and is produced in both peripheral and central neurons.  It is abundant in trig eminal neurons and when released  is involved in the vasodilation, 
inflammatory cascade, and pain transmission asso ciated with migraine. In both peripheral and 
central pain pathways CGRP is associated with pain transmission and neuronal sensitization.
9
Intravenous (IV) infusions of CGRP can cau se a migraine-like headache in susceptible 
individuals with migraine.10In addition, many pharmacological agents used as acute or 
prophylactic treatment of migraine are known to inhibit CGRP. Thus, CGRP is an attractive 
target for development of novel migraine pharmacology.
Currently the pharmacological treatment of migraine  can be divided into ac ute treatment, that is, 
medications designed to reverse a migraine after it is initiated and preventive treatment that is 
designed to protect the nervous system from generating migraine. Acute treatments are used 
intermittently only as needed to stop an attack while preventative treatments are used on a sustained basis for periods of months to years.  Acute treatment while generally quite effective 
can worsen the severity and frequency of migrai ne when used too frequently, a condition called 
medication overuse headache (MOH).
4MOH is common in populations with frequent epi[INVESTIGATOR_229175].[ADDRESS_385843] been designed 
specifically for migraine. These commonly include tricyclic antidepressants, beta-blockers, and certain anticonvulsants. It is es timated that 45% of adults with  frequent epi[INVESTIGATOR_313386] 12% of this population are currently using a migraine preventive.
1In large 
measure, this is due to poor tolerability, lack of efficacy, and failure to adhere to treatment.  Clearly there is a medical need to develop effective, well-tolerated and safe preventive 
treatments for migraine. 
Protocol ALD403-CLIN-[ADDRESS_385844]
ALD403 is a genetically engin eered humanized immunoglobulin G1  (IgG1) antibody that binds 
to human- ƒÆ-CGRP with an affinity of 1.5E-11 M and human- »ï-CGRP with an affinity of 
5.7E-11 M.
5.3.1. Summary of Nonclinical Studies
A nonclinical testing program has been conducte d supporting the use of ALD403 in clinical 
trials. More detailed discussion is provided in the current version of the ALD403 Investigator‚Äôs 
Brochure (IB).
$/'LVDJHQHWLFDOO\HQJLQHHUHGKXPDQL]HG,J*DQWLERG\WKDW ELQGVWRƒÆ -DQG»ï - forms of 
KXPDQF\QRPROJXVPRQNH\DQGUDW &*537KHDPLQRDFLGVHTXHQFH IRUƒÆ -DQG»ï -CGRP is 
identical in cynomolgus monkeys and humans (data on file); therefore, the in vitro binding 
characteristics of cynomolgus monkey and human CGRP to ALD403 would be 
LQGLVWLQJXLVKDEOH5DWƒÆ -&*53LVRQHDPLQRDFLGGL IIHUHQWIURPKXPDQƒÆ -&*53DQGUDW»ï -CGRP 
LVDPLQRDFLGVGLIIHUHQWIURPKXPDQ»ï -CGRP. Based on comparable binding affinity and in 
vitro SRWHQF\IRUUDWF\QRPROJXVPRQNH\DQGKXPDQƒÆ -DQG»ï -CGRP, the rat and cynomolgus 
monkey were selected for nonclinical safety assessments.
Pharmacodynamic activity by [CONTACT_169032]403 in the specie s selected for toxicological investigations 
(rats, rabbits, and monkeys) was c onfirmed in vivo by [CONTACT_313403]403 to inhibit CGRP-mediate d neurogenic dermal vasodilation.
In the single-dose nonclinical toxicology studies , the no-observed-adverse-effect-level (NOAEL) 
for IV administration of ALD403 to rats and cynomolgus monkeys was 100 mg/kg.
Toxicological investigations in rats and monkeys  indicated that repeated -dose IV administration 
of ALD403 at 10, 30, or 100 mg/kg once weekly for four weeks was well to lerated, with no signs 
of adverse effects related to treatment. Under the conditions of these studies, the no-observed-
adverse-effect-level (NOAEL) for once weekly IV  administration of ALD403 to rats or monkeys 
for four weeks was 100 mg/kg.
A chronic multiple-dose toxicology study in cyno molgus monkeys was conducted to evaluate the 
potential effects by [CONTACT_169032]403 following 6-months administration via slow bolus injection once 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 18of 78every two weeks (a total of fourteen dosing occasions) at 0, 20, 50, or 150 mg/kg/dose followed 
by a three month recovery period in select animals. 
Following the sixth dosing occasion on study day 71, one low-dose (20 mg/kg/dose) female 
animal exhibited an anaphylactoid-like reacti on and died within approximately [ADDRESS_385845].Administration of ALD403 via intravenous (s low bolus) injection once every 2 weeks for 
approximately 6-months (for a to tal of 14 doses) did not result in  any treatment-related effects 
upon the parameters evaluated in this study.  The NOAEL for ALD403 following chronic 
administration in monkeys was considered to be 150 mg/kg/dose (Day 183 mean C
maxof 
19,600/6,160 »ùg/mL; mean AUC (0-2wk) of 1,610,000/904,000 »ùg¬∑h/mL for males/females, 
respectively).
ALD403 is not expected to interact directly with DNA or other chromo somal materials, and 
genotoxicity assessments have not been conducte d. The carcinogenic potential for ALD403 has 
not been thoroughly investigated. The results of toxicological and clinical investigations to date 
with ALD403 have provided no indications of effe cts with the potential to support or induce the 
proliferation of malignant cells.
Definitive embryo-fetal devel opment studies with ALD403 in rats and rabbits have been 
conducted.  The administration of  ALD403 by [CONTACT_33980] (slow bolus) injection to pregnant 
female rats on Days 6, [ADDRESS_385846] coitum, at 75 or 150 mg/k g/dose was well tolerated, and there was no 
evidence of embryo-fetal mortality (embryolethality), alterations in growth (fetotoxicity), or 
structural abnormalities (teratogenicity) in either species.  
The local tolerance of ALD403 was assessed following repeated-(once weekly) dose studies in 
rats and cynomolgus monkeys utilizing ALD 403 administered IV. Following the end-of-
treatment, no gross or microscopi c lesions were observed in the ALD403 injection sites excised 
from rats. In the injection sites obtained from cynomolgus monkeys, only procedure-related 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 19of 78findings were observed and included (in order of  decreasing incidence) minimal and/or mild 
superficial perivascular infiltrates, fibroplasia/f ibrosis, myointimal hyperplasia of the injected 
vein, hemorrhage, and sporadic observations in the epi[INVESTIGATOR_169010]. 
5.3.2. Summary of Clinical Trials
Detailed descriptions of the relevant clinical findings for ALD403 are provided in the 
Investigator‚Äôs Brochure (IB).
A summary of completed and ongoing ALD403 clinical trials is shown in Table 5.3.
Table 5.3 ALD403 Clinical Trials
Trial ID Phase/ObjectiveTrial Subject 
PopulationTotal 
Number of 
Subjects in 
the TrialNumber of 
Subjects 
Randomized to 
ALD403Number of 
Subjects 
Randomized 
to Placebo
ALD403-CLIN-001
(completed)Phase 1
SafetyHealthy 
Volunteer1 104 67 37
ALD403-CLIN-002
(completed)Phase 1b
Safety & EfficacyFrequent 
Epi[INVESTIGATOR_169011]163 81 82
ALD403-CLIN-003
(completed)Phase 1
SafetyHealthy 
Volunteer60 36 24
ALD403-CLIN-007
(completed)Phase 1
(Safety)Healthy 
Volunteer60 49 11
ALD403-CLIN-009
(completed)Phase 1
(Safety)Healthy 
Volunteer36 24 12
ALD403-CLIN-005
(completed)Phase 2 
Safety & EfficacyChronic 
Migraine665 531 134
ALD403-CLIN-0062
(ongoing)Phase 3 
Safety & EfficacyFrequent 
Epi[INVESTIGATOR_169011]900
ALD403-CLIN-0101
(completed)Phase 1
(Safety)Healthy 
Volunteer2416 8
ALD403-CLIN-0112
(ongoing)Phase 3 
Safety & EfficacyChronic 
Migraine1121
ALD403-CLIN-0121
(ongoing)Phase 1
(Safety)Type 1 Diabetic 
(T1DM)[ADDRESS_385847] common observed 
adverse events (>5%) with receiving ALD403 or placebo included upper respi[INVESTIGATOR_4348], back pain, dizziness, ar thralgia, urinary tract infection, and headache.  The majority of 
these adverse events were categorized as mild to moderate.
Long term data with ALD403 is limited. 
xHealthy volunteer trials have included limited dosing, short duration of follow up and 
have not included long term follow-up.
xTrials in migraine patients have also included limiting dosing.  These trials are currently ongoing and no new significant findings have been noted during the follow-up period to date.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 21of 78The safety findings to date indicate that ALD403 Injection is well tolerated, with ALD403 
demonstrating a favorable benefi t-risk profile based on review  of nonclinical, clinical, and 
scientific literature data.
The sponsor will continue to monitor for sign ificant new information and suspected adverse 
reactions associated with the use of ALD403.
5.5. Compliance Statement
This clinical trial will be c onducted in accordance with standa rds of Good Clinical Practice 
(GCP) as defined by [CONTACT_313404] (ICH ) and all applicable 
federal and local regulations.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 22of 786. OBJECTIVES
6.1. Safety Objective
The primary objective is:
xTo evaluate the long term safety of repeat doses of ALD403 administered intravenously (IV) 
in chronic migraine patients 
6.2. Immunogenicity and Patient Reported Outcomes
The secondary objective is:xTo evaluate the pharmacokinetics (PK) a nd immunogenicity of repeat doses of ALD403 
administered IV to patients with chronic migraine.
xTo further evaluate the impact of AL D403 on various patient  reported outcomes.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 23of 787. TRIAL DESIGN
7.1. Clinical Trial Endpoints
7.1.1. Safety Endpoints
xAdverse events (AEs) and serious adverse events (SAEs)
xClinical laboratory assessments 
xVital Signs
xECGs  
xColumbia-Suicide Severity Rating Scale (C-SSRS)
7.1.2. Patient Reported Outcomes:
xPatient Global Impression of Change (PGIC) 
xShort-Form Health Survey (SF-36)
xHealth-Related Quality of Life (EQ-5D-5L)
xHeadache Impact Test (HIT-6)
xMost Bothersome Symptom (MBS)
xThe Migraine Disability Assessment (MIDAS)
7.1.3. PK and Immunogenicity Endpoints: 
xFree ALD403 plasma concentrations 
xDevelopment of specific anti-ALD403 antibodies
xCharacterization of specific anti-ALD 403 antibodies for neutralizing activity
7.2. Clinical Trial Design
This is an open label trial of intravenous (IV) infusions of ALD403 in patients with chronic 
migraine.  The trial will include two treatment phases.  The primary treatment phase will include
4 infusions of ALD403 12 weeks apart. The seco ndary treatment phase will include up to 4 
additional infusions of ALD403 12 weeks apa rt following the primary treatment phase.
Subjects who provide informed consent will be evaluated for eligibility based upon the inclusion 
and exclusion criteria. In the primary treatment phase, visits will occur on Day 0, Weeks 2, 4, 8, 
12, 24, and 36 and subjects will receive 4 IV infusions of ALD403 on Days 0, Weeks 12, 24, and 
36.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 24of 78Subjects who receive all 4 infusions of ALD403 in the primary treatment phase may enter the 
secondary treatment phase. In th e secondary treatment phase, subjects will receive up to 4
additional infusions for a total of 8 infusions . Visits and ALD403 IV infusions will occur on 
Weeks 48, 60, 72, and 84. Subjects will be follo wed for 20 weeks until Week 104 for a total 
study duration of approximately 106 weeks, including the screening period. 
Subjects who don‚Äôt receive all 4 infusions of AL D403 in the primary treatment phase or don‚Äôt 
consent for participation in th e secondary treatment phase w ill be followed at Week [ADDRESS_385848] meet all of the following criteria du ring the screening period and on Day 0 to be 
eligible for inclusion in the trial:
1. Willing and able to read and understand the consent pro cess and sign an Informed 
Consent Form (ICF) for the clinical trial approved by [CONTACT_3551] 
(IRB) or Ethics Committee (EC).
2. Male or female 18 ‚Äì 65 years of age inclusive at time of informed consent.3.'LDJQRVLVRIPLJUDLQHDW¬î\HDUVRIDJHZLWKKLVWRU\RIFKURQLFPLJUDLQH¬ï\HDU
(ICHD-3 beta, 2013 Section 1.3).
4. Prescription or over-the-count er medication for acute and/or  prophylactic treatment of 
migraine has been prescribed or reco mmended by a health care professional.
5. Women of child-bearing potential, and males with partners of child-bearing potential, 
must agree to use adequate contraception for six months after last dose of study drug.   
Adequate contraception includes oral, transdermal or injectab le [depot] estrogen, and/or 
progestogen, selective estrogen receptor modul ator therapy, intrauterine contraceptive 
device, double barrier method (e.g., condom and diaphragm or spermicidal gel) or 
vasectomy.  Non-childbearing potential is defi ned as post-menopausal for at least [ADDRESS_385849] and 
collection of blood samples.
7. Any hormonal therapy (e.g., contraceptives, hor mone replacement therapy) use is stable 
and ongoing for at least [ADDRESS_385850] 3 months 
prior to screening.  
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 26of 7810. Limited use of barbiturates (including Fiorinal¬Æ, Fioricet¬Æ, or any other combination 
containing butalbital) or prescr iption opi[INVESTIGATOR_313387] a stable dose is maintained for 
[ADDRESS_385851] any personal medical data related to the trial or information 
related to the trial on any we bsite or social media site (e.g., Facebook, Twitter) during the 
trial.
8.2. Exclusion Criteria
A subject who meets any of the following criteria will be excluded from the trial:
1. Receipt of any monoclonal antibody trea tment, including ALD403 or any monoclonal 
antibody targeting the CGRP pathway (within or  outside a clinical trial) within 6 months 
before screening.
2. Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low 
back pain, complex regional back sy ndrome, temporomandibular disorders).
3. Psychiatric conditions that are uncontrolled and/or untreated, including conditions that 
are not controlled for a minimum of 6 months  prior to screening.  Patients with a 
lifetime history of psychosis, mania, or dementia are excluded.
4. History or diagnosis of complicated migra ine (ICHD-III beta version, 2013), chronic 
tension-type headache, hypnic headache, cluster headache, hemic rania continua, new 
daily persistent headache, or sporadic and familial hemiplegic migraine 
5. Any use of approved devices, neuromodulation, neurostimulation or injectable therapy 
(trigger point injections, extracranial nerve blocks, facet joint for headache prophylaxis 
are prohibited 2 months prior to screening and during screening. 
6. Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons 
requiring injections in the head, face, or neck within 4 months prior to screening and 
during screening. 
7. Any use of monoamine oxidase inhibito rs (MAOIs), ketamine, methysergide, 
methylergonovine, or nimesulide within [ADDRESS_385852] present or previous malignancies, except:
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 27of 78xSquamous or basal skin cell carcinoma with  excision, without evidence of recurrence, 
or
x0DOLJQDQF\¬ï\HDUVVLQFHGLDJQRVLVWUHDWPHQWZLWKRXWHYLGHQF HRIUHFXUUHQFH
9. Subject has known history or evidence of cardiovascular diseas e, arteriosclerosis, 
cardiomyopathy, coronary artery diseas e, serious heart rhythm abnormalities, 
neurological disease, cerebrovascular dis ease, diabetes, Raynaud‚Äôs disease, or life-
threatening allergy (e.g, anaphylaxis).  If que stions arise, the Investigator should contact 
[CONTACT_27882].  
10. Primary hypertension that is uncontrolled or  newly diagnosed (systolic BP of >139 mm 
Hg or diastolic BP of >89 mm Hg) at screening or secondary hypertension. Mild 
primary hypertension that is well- FRQWUROOHGIRU¬ïPRQWKVSULR UWRVFUHHQLQJLVDOORZHG
11. Clinically significant abnormal ECG at screening or on Day 0. 
12. Any clinically significant concurrent medical condition or clinically significant 
laboratory abnormality at screening or on Day 0.
13.%RG\0DVV,QGH[%0,¬ïNJPDWVFUHHQLQJ
14. The subject is at risk of self-harm or harm  to others in the investigator‚Äôs opi[INVESTIGATOR_1649], based 
on clinical interview and responses provide d on the Columbia-Suicide Severity Rating 
Scale (C-SSRS).  Subjects must be excluded if they have a lifetime history of a serious 
suicide attempt or multiple suicide attemp ts (i.e., actual, interrupted, or aborted 
attempts), had any suicidal behavior in the past 5 years (i.e., preparatory acts or behavior), or had suicidal id eation of Type 3, 4 or 5 (i.e ., suicidal ideation with any 
method without intent to act or suicidal ideation with intent to act, with or without a plan), in the past 6 months , as measured by [CONTACT_941] C-SSRS at screening or on Day 0.
15. Any history or evidence of substance abuse or dependence (e.g., alcohol, opi[INVESTIGATOR_858], 
amphetamines, and barbiturates) within the past 2 years according to the International Classification of Diseases (ICD) 10: F10-19.
16. Pregnant, breastfeeding, or planning  to become pregnant during the trial.
17. Receipt of any experimental, unregistered therapy (within or outside a clinical trial) 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 28of 78within 30 days or 5 plasma half-lives (whichever is longer) before screening.
18. Planned or current par ticipation in any other clinical trial for the duration of this clinical 
trial, or within 6 months prior to screening. NOTE: Subjects who participated in prior 
clinical trials of CGRP an tagonists, including ALD403-CLIN-005, may be eligible to 
participate if they 
xhad their last dose of study drug more th an [ADDRESS_385853] unsuitable 
for the clinical trial.
22. Employees of Alder, the CRO(s), or any clinical trial site involved in  this trial and their 
immediate family members (i.e., parents, spouse, siblings, children). 
8.3. Registration and Treatment Assignment
8.3.1. Registration Procedure, Subject Numbering
Each participating investigative site will be assigned a 3-digit site number (e.g., 101, 102). At the 
screening visit, once the subject signs the ICF they are registered in the Interactive Web 
Response System (IWRS), which will assign a unique  subject number. The first three digits of 
the subject number identify the site, and the remaining digits identify the subject.
Subjects who fail screening may be rescreened if approved in advance by [CONTACT_1689].  
8.4. Subject Treatment Discontinuation and Early Withdrawal
Subjects may discontinue treatment or withdraw fr om the clinical trial at any time and for any 
reason without penalty or prejudice to  his or her future medical care. 
8.4.1. Criteria for Discontinuat ion from Study Treatment
Study treatment must be discontinued for the following reasons:
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 29of 78xPregnancy
xSuicidal ideation with intent, with or without a plan (i.e., ‚ÄòYes‚Äô to suicidal ideation 
questions 4 or 5) or any suic idal behavior as determined by [CONTACT_941] C-SSRS.       
Subjects discontinued due to suicidal ideation and/ or suicidal behavior must be referred to a 
mental health specialist as specified in Section 11.1.9.
Study treatment may also be discontinued for the following reasons:
xAdverse Event
xSubject decision
xInvestigator decision 
xTermination of the study by [CONTACT_313405] a subject discontinues study treatment due to  a medical condition, Inve stigators must provide 
adequate medical treatment during study visits .  Prior to removing a subject from study 
treatment, the decision should be discussed with the Medical Monitor or designee. The reason for 
discontinuation from study treatment must be recorded on the CRF. Subjects who discontinue 
study treatment will be encouraged to continue with study assessments until the end of the study.
8.4.2. Criteria for Withdrawal from the Clinical Trial
Subjects will be withdrawn from the clinical trial for any of the following reasons:
xWithdrawal of consent for the collection of clinical trial data including further access 
to medical records. The reason for withdrawal of consent will be recorded.
xTermination of the trial by [CONTACT_313406]-up
The reason for withdrawal and the date of withdrawal must be recorded on the CRF.
[IP_ADDRESS]. Timing of Withdrawal
Subjects are considered withdrawn from the clinical trial at the time that any of the criteria listed 
in Section 8.4.[ADDRESS_385854]  study assessment is performed.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 30of [IP_ADDRESS]. Follow-up for Early Withdrawal
Subjects who withdraw early from study participation due to any reasons will be asked to have 
an early termination visit with associated visit assessments (see Schedule of Events in Section 2 ).  
Subjects who withdraw consent after screening but do not receive study treatment may discontinue the study without  any further procedures.
8.4.3. Replacement Policy
Subjects who are withdrawn from the clinical  trial after dosing will not be replaced. 
8.4.4. Lost to Follow-UpIf the subject fails to attend scheduled study vi sits or to respond to requests for follow-up, the 
clinical trial site will send a registered letter, at a minimum, to the subject requesting contact [CONTACT_313407].  All attempts to resume contact (incl uding copi[INVESTIGATOR_313388]) will be included in the source documentation.  Subjects who do not respond to requests for follow-up after all reasonable 
attempts to establish contact [CONTACT_313408]-up.
Protocol ALD403-CLIN-[ADDRESS_385855] 
ALD403 is an anti-(calcitonin gene-related pe ptide) humanized monoclonal antibody (anti-
CGRP mAb) that is being developed by [CONTACT_313409].  
ALD403 Injection, 100 mg/vial, is presented in 2-mL Type I glass vials as a single-use 
preservative-free solution for IV administration.  ALD403 is formulated at a concentration of 
100 mg/mL with a pH of 5.8.  Subjects will receive an IV infusion of ALD403 300 mg Injection 
in 100 mL of 0.9% saline.  
9.2. Investigational Product Administration
ALD403 (approximate volume of 100 mL) is administered IV over a period of 30 ( +15) minutes 
at the visits specified in Schedule of Events in Section 2, by [CONTACT_18370]. 
Infusions may be administered for a total duration of up to [ADDRESS_385856] experiences a headache or migraine on dosing day, dosing may occur if, in the 
investigator‚Äôs opi[INVESTIGATOR_1649], it will not compromise the sa fety of the subject.  The Medical Monitor 
may be consulted as needed.  Subjects must remain in the care facility and be monitored by [CONTACT_313410] [ADDRESS_385857] for the occurrence of adverse events. Subjects will be requested to stay longer than 2 hours after the end of infusion should the i nvestigator determine it is clinically warranted 
(i.e., subjects should be observed until all AEs are resolved or clinically stable).  The timeframe for the post-dose observation period must be documented in the source record.
Further instructions on ALD403 preparation and administration can be found in the Pharmacy 
Manual.
Protocol ALD403-CLIN-[ADDRESS_385858]
ALD403 will be stored at a central depot  or at the clinical site at -20¬∞C (-10¬∞C to -25¬∞C) in 
accordance with any accompanying instructions.  Please refer to the Pharmacy Manual for 
additional storage and handling pr ocedures.  Diluent (0.9% saline)  will be stored according to 
manufacturer instructions.
Investigators shall take adequate precautions, including storage of ALD403 in a securely locked, 
substantially constructed cabinet or other secure ly locked, substantially constructed enclosure, 
access to which is limited to prevent theft or diversion of the substance into illegal channels of distribution.
9.2.3. Accountability and Disposition of ALD403
The Investigator is responsible for mainta ining accurate ALD403 accountability records 
throughout the clinical trial. The site must ma intain an Investigational Product Accountability 
Logas per the study Pharmacy Manual. Where more than one secure area is being used for 
storage at a site, all movement of ALD403 throu gh the chain of custody must be recorded in 
accountability records such that full reconciliation may be completed at the end of the trial. 
Included with each ALD403 shipment is a form  listing lot numbers and quantity shipped. The 
Investigator, responsible pharmacist, or designee, will sign and return to Alder, or designee, a 
statement that certifies the receipt and integrity of these supplies. A copy will be retained for the 
site clinical trial file.
After completion of the clinical trial, the Inve stigator is responsible for either returning or 
destroying all unused ALD403. The Investigator mu st verify that no remaining supplies are in 
his/her possession. All used/partially used vials/IV bags will be destroyed onsite according to the 
site SOPs or returned according to Alder directive. Destruction must be in accordance with local 
regulations for the product type and destructi on documentation must be provided to Alder.  
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 33of 78If the clinical trial is terminated, suspended, discontinued, or complete d, the Investigator or 
designee shall return the unused supplies to Alder or designee, or otherwise provide for 
disposition of the unused supplies (as authorized by [CONTACT_313411]). 
9.3. Concomitant Medications
Any concomitant therapy used from the time the subject signs the informed consent through 
Week [ADDRESS_385859] be recorded. The 
Medical Monitor or designee shoul d be notified in advance of (or as soon as possible after) any 
instances in which restricted therapi[INVESTIGATOR_23730]. 
Subjects on stable medication for headache prophylaxis for [ADDRESS_385860]‚Äôs primary treating healthcare professional. 
A list of the migraine preventive therapi[INVESTIGATOR_313389] 15.1 for reference. Sites are required to indicate if a medication is used for prophylaxis 
purposes or if it is used for th e acute treatment of migraines.
The following medications are restricted:
xPrescription EDUELWXUDWHVDQGRSLDW HVDUHDOORZHGIRU¬îGD\VSHUPRQWKSUR YLGHGWKH
VXEMHFWKDVEHHQRQDVWDEOHUHJ LPHQ¬îGD\VSHUPRQWKIRUD WOHDVWPRQWKVSULRUWR
screening and throughout the entire trial. After enrollment, the use of prescription 
barbiturates and opi[INVESTIGATOR_313390] a licensed 
healthcare professional for indi cations other than migraine.
xBotulinum toxin for migraine or for any other medical/cosmetic reasons requiring 
injections in the head, face, or neck are prohibited 4 months prior to screening and 
throughout the entire trial.
xDevices, neuromodulation, neur ostimulation, or injectable therapy (trigger point 
injections) for headache prophylaxis are pr ohibited 2 months prior to screening and 
throughout the entire trial.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 34of 78xAny use of monoamine oxidase inhibitors  (MAOIs), ketamine, methysergide, 
methylergonovine, or nimesulide within [ADDRESS_385861] was recru ited to the trial will be 
collected in source records and in the CRF.  
10.2.2. Medical History
Significant historic and current medical conditions or illnesses, allergies to medications, and 
prior surgical interventions will be recorded in the source records and in the CRF.  Symptoms 
that are ongoing at the time of informed consent will be considered medical history.
Migraine history will also be collected in the source records and the CRF, including age at 
diagnosis of chronic migraine as well as other deta ils of the subjects‚Äô history with migraine.  If 
the subject is not a current or past user of a prescribed medication for migraine, the Medical 
Monitor should be consulted.  
Investigators should demonstrate due diligence in tr ying to obtain medical records.  All attempts 
to obtain medical records should be documented.  If medical records cannot be obtained, history 
may be confirmed via patient interview in order to obtain sufficient information to confirm all 
eligibility criteria are met.
10.2.3. Physical Examinations
Physical examinations will be performed at the times noted in the Schedule of Events in 
Section [ADDRESS_385862] ems reviewed will be at the discretion of the 
Investigator.  
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 36of 78Physical examination may include weight measurement as specified in Schedule of Events in 
Section 2.  Height will be measured at screening only.
Abnormal physical examination findings at the screening visit will be recorded as medical 
history.  Any new or worsening physical examination finding identified after informed consent 
will be considered an AE.
10.2.4. Vital Signs
Vital signs, including blood pressure (BP) and pulse will be measured at the time points specified 
in the Schedule of Events in Section 2.
When measuring vital signs, the subject should be  seated comfortably, with back supported and 
rested for [ADDRESS_385863] 80% around the arm.  The center of the bladde r should be in line with the brachial artery so 
as to allow the stethoscope diaphragm clear access to the brachial artery.  Site staff and subject should refrain from talking during the reading.  Blood pressure may be repeated to confirm 
measurement.
10.2.5. Questionnaires
Questionnaires should be administe red to subjects in the order listed below at the time points 
specified in the Schedule of Events in Section 2:
1. Columbia-Suicide Severi ty Rating Scale (C-SSRS)
2. Most Bothersome Symptom (MBS)
3. Patient Global Impre ssion of Change (PGIC)
4. Short-Form Health Survey (SF-36)5. Health-Related Quality of Life (EQ-5D-5L)
6. Headache Impact Test (HIT-6)
7. The Migraine Disability Assessment (MIDAS)
Protocol ALD403-CLIN-[ADDRESS_385864] should be asked to complete any unanswered 
questions.
[IP_ADDRESS]. Columbia-Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS will be administered by [CONTACT_23872] (i.e ., C-SSRS certified) site staff at the time points 
specified in the Schedule of Events in Sectio n 2.  The C-SSRS must be administered prior to 
dosing at dosing visits. The C-SSRS ‚ÄúBaseline/Screening‚Äù version will be used for the screening 
visit, and the C-SSRS ‚ÄúSince Last Visit‚Äù version will be used for all subsequent visits.
[IP_ADDRESS]. Most Bothersome Symptom (MBS)
The Investigator will verbally obtain the most bothersome symptom associated with the subject‚Äôs 
migraines during the screening visit.  The most bothersome symptom will be captured in the 
eCRF and may include nausea, vomiting, sensitiv ity to light, sensitivity to sound, mental 
cloudiness, fatigue, pain with activity, mood changes, or other migraine related symptom.  
At each subsequent visit, the site staff will provide the questionnaire along with the other 
subject-completed questionna ires listed in Section 10.2.5.
[IP_ADDRESS]. Other Questionnaires
The following questionnaires will be administered at days and times provide d in the Schedule of 
Events in Section 2.  Subjects will be given the questionnaires in the order specified below and 
asked to review the brief instructions  on each questionnaire and complete.    
xPatient Global Impression of Change (PGIC)
xShort-Form Health Survey (SF-36)
xHealth-Related Quality of Life (EQ-5D-5L)
xHeadache Impact Test (HIT-6)
xThe Migraine Disability Assessment (MIDAS)
Protocol ALD403-CLIN-[ADDRESS_385865] be performed prior 
to dosing and up to 2 hours (+ 30 min) after dosing.
ECG data will be transmitted and read centrally by a cardiologist, however, the Investigator must 
review the ECG to ensure there are no clinically  significant abnormalities prior to dosing.  In 
addition, all centrally read ECG re ports must be reviewed by [CONTACT_313412]. 
All ECGs are expected to be performed on the ECG device provided to the site by [CONTACT_313411].  A 
local ECG device may be used only in the event that there are technical issues with the central 
ECG device that cannot be resolved while the subj ect is onsite.   All technical issues must be 
reported immediately to the ECG vendor help desk.
10.2.7. Laboratory Samples and Testing
[IP_ADDRESS]. Urine Drug Screening
Drugs of abuse testing will be performed on urine sa mples during the screening visit.  Urine drug 
screen kits will be provided by [CONTACT_313413].
[IP_ADDRESS]. Pregnancy Testing
Urine pregnancy tests will be performed for a ll female subjects, regardless of childbearing 
potential, at the specified time points in the Schedule of Events, Section 2.  On dosing visits 
urine pregnancy tests must be performed prior to dosing.
Urine pregnancy test kits will be provided by [CONTACT_6626], and the test performed on site.
The contraceptive method used by [CONTACT_313414]-bearing potential and males with partners of 
child-bearing potential must be confirmed with the subject and recorded in the source record at 
screening, and reconfirmed with the subject and r ecorded in the source record at each subsequent 
study visit.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 39of 7810.2.7.3. Clinical Laboratory Testing
Blood samples for clinical laborat ory tests, including hematology , serum chemistry and serology 
(including HIV, Hepatitis B, and Hepatitis C), will be collected at the time points specified in the 
Schedule of Events in Section 2.  Clinical la boratory tests performed are listed in Section 11.1.7.
All clinical laboratory samples will be initially pr ocessed by [CONTACT_313415] a central 
laboratory for analysis as specified in the Laborat ory Manual.  An Investigator listed on the Form 
FDA 1572 will review all lab reports  and document clinical signifi cance for any out-of-range lab 
value(s) listed in the report.  
[IP_ADDRESS]. Pharmacokinetic and Immunogenicity Sampling
Blood samples will be collected for ALD403 plas ma PK and for deter mination of anti-ALD403 
antibodies in serum (immunogenicity) at specified time points in the Schedule of Events in 
Section 2.  All samples will be initially processed, stored, and shipped as specified in the 
Laboratory Manual.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 40of 7811. ASSESSMENT OF SAFETY
11.1. Adverse Events
11.1.1. Definitions
An adverse event (AE) is any untoward medical occu rrence in a patient or clinical investigation 
participant administered a pharmaceutical prod uct that does not necessarily have a causal 
relationship with the treatment.  An AE can th erefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), sympto m, or disease temporally associated with the 
use of a medicinal (investigational) product , whether or not related to the medicinal 
(investigational) product. (ICH E6)
11.1.2. Assessment of Adverse Events
The Investigator is required to monitor the o ccurrence of adverse events for each subject from 
the time of informed consent through the course of  the clinical trial.  Adverse events may be 
reported by [CONTACT_423], reported by a caregiver, or reported by [CONTACT_313416]-ended questioning, through physical examination, laboratory 
test, documentation in medical records, or by [CONTACT_11174].  Adverse events include:
xAny new undesirable medical experience or an unfavorable and unintended change of an 
existing condition that occurs during or after treatment, whether or not considered related 
to the Investigational Product.
xAny abnormal assessment or laboratory findings considered by [CONTACT_313417].  Clinically significant findings include but are not limited to those 
that lead to discontinuation or interrupti on of study treatment, require therapeutic 
intervention, or require a change in subject management.
A new or worsening of a pre-existing or chroni c condition is considered an adverse event and 
must be reported as such.  Medical conditions, which existed prior to the time of informed consent into the clinical tria l, will not be considered an a dverse event unless the condition 
worsens.  Unchanged, chronic, non-worsening or pre-existing conditions from the time of 
informed consent are not adverse events and should not be recorded on the AE eCRF.  
Protocol ALD403-CLIN-[ADDRESS_385866]‚Äôs medical 
history and recorded on the medical history eCRF page. 
Each event recorded on the AE eCRF is required to  be assessed by [CONTACT_313418]; seriousness, severity, and relationship to ALD403, as outlined below.Seriousness
An adverse event or suspected adverse event is considered serious if in the view of either the 
Investigator or Alder, it results in;
xDeath
xIs life-threatening (this means that the subject is at risk of death at the time of the event; it 
does not mean that the event hypothetically might have caused death if it were more 
severe)
xInpatient hospi[INVESTIGATOR_313391]. 
xA persistent or significant incapacity or s ubstantial disruption of the ability to conduct 
normal life functions. 
xCongenital anomaly/ birth defect
xImportant medical events that may not result in death, be life-threatening or require hospi[INVESTIGATOR_708], based upon appropriate medical judgement, they may jeopardize the patient or subject and/or may require medical or 
surgical intervention to prevent one of the outcomes listed in the definition (
21 CFR 
312.32(a) and ICH E2A).
Of note: 
oA social hospi[INVESTIGATOR_059] (i.e., hospi[INVESTIGATOR_313392]-admissions not due to an 
acute medical issue) is not considered an SAE.
oHospi[INVESTIGATOR_29919] a grea ter than 24 hour hospi[INVESTIGATOR_063].
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 42of 78Severity
The severity of an AE will be graded as follows:
xGrade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
xGrade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-
appropriate instrumental Activities of Daily Living (ADL).
xGrade 3 Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care ADL.
xGrade 4 Life-threatening consequenc es; urgent intervention indicated.
xGrade 5 Death related to AE.
Relationship to ALD403
The Investigator is required to assess the ca usality/relationship betw een each AE and the 
ALD403 as not related or related and record th e assessment on the source documents and in the 
eCRF AE page. Medical judgment should be used to determine the likely relationship of the AE 
to the ALD403 considering all relevant factors including (but not limited to) relevant history, 
concomitant medical condition, and concomitant medications.  De termination should be based 
on assessment of temporal relationships, biologic pl ausibility, association (or lack of association) 
with underlying disease, and presence (or absence) of a more likely cause.  
Not Related: It is plausible that the AE has an etiology other than the ALD403 (e.g., pre-
existing condition, underlying disease, conc omitant medical condition, or concomitant 
medication).Related: The AE cannot reasonably be explaine d by [CONTACT_423]‚Äôs clinical state,
concomitant\medical condition or concomitant therapi[INVESTIGATOR_014], and a temporal relationship 
exists between the event onset and administration of the ALD403. 
Protocol ALD403-CLIN-[ADDRESS_385867] be reported if the 
Investigator considers there to be a causal relationship with ALD403. 
An SAE Notification Form should be used to repo rt any related SAEs which occur after the end 
of the clinical trial. Adverse events (AEs) should be recorded on the AE eCRF, whether believed by [CONTACT_313419]403. 
AE reporting should contain:
xA brief description of the event
xDate of onset 
xDate of resolution
xSeverity
xActions taken or treatment required 
xRelationship to Inve stigational Product 
xOutcome 
xWhether the event is considered serious
Whenever possible, the Investigator should group signs or symptoms that constitute a single 
diagnosis into a single event term.  For example, ‚Äúcough, rhinitis, and sneezing‚Äù might be 
grouped together as ‚Äúupper respi[INVESTIGATOR_1092].‚Äù
Asymptomatic abnormal findings considered by [CONTACT_3433] e Investigator to be clinically significant 
should be recorded as an AE, unless it is associated with a clinical syndrome that has already 
been reported as an AE.
11.1.4. Reporting Seriou s Adverse Events
All SAEs that occur during the period of obser vation, whether considered  to be related to 
ALD403 or not, must be reported within [ADDRESS_385868] be recorded in the source 
document.  To report the SAE, complete the eCRF AE page and indicate the reason for 
seriousness.  The minimum information required for an initial report is:
xSender of report (name, address of Investigator)
xSubject identification (screening/enrollment number, NOT subject name)
xProtocol number
xDescription of SAE (e.g., event term)
xSeriousness criteria
xRelationship assessment
After receipt of the initial repor t, the Medical Monitor or designee will review the information 
and, if necessary, contact [CONTACT_169049].  Alder, or Alder‚Äôs designee will be res ponsible for information processing and reporting in 
accordance with applicable local and regulatory requirements. 
Alder will determine if an SAE requires expedited reporting to regulatory agencies.  The clinical 
trial site personnel are responsible  for reporting these events to their EC/IRB according to the 
institution‚Äôs EC/IRB reporting requirements a nd in accordance with applicable local and 
regulatory requirements.
Should the EDC System not be available, serious  adverse events must be reported on the paper 
SAE Notification Form. Additiona l details can be found in the Site Manual. This does not 
replace the EDC reporting system; information must be entered in the EDC system once the 
system returns to normal function.
11.1.5. Unexpected and Relate d Serious Adverse Events
Unexpected SAEs are those which:
xAre not previously reported as associat ed with ALD403, as referenced in the 
Investigator‚Äôs Brochure.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 45of 78xMay be symptomatically and pathophysiologically related to an AE listed in the 
Investigator‚Äôs Brochure, but differ from the ev ent due to greater severity, frequency, or 
specificity.
Alder, or Alder‚Äôs designee will report, to the appropriate regulatory authorities according to local and regulatory requirements, unexpected SAEs  which are considered related to ALD403 
(suspected unexpected serious a dverse reactions [S[LOCATION_003]Rs]).  The clinical trial site personnel are 
responsible for reporting these events to their EC /IRB in accordance with applicable local and 
regulatory requirements.
11.1.6. Follow-up of Adverse Events
Irrespective of the suspected causality, AEs w ill be monitored until resolution, stabilization in 
the judgment of the Investigator, or the subject is lost to follow up or withdraws from the trial.
11.1.7. Clinical Laboratory TestsSerum chemistry tests include albumin, alkaline phosphatase (ALP ), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), ur ea nitrogen, calcium, bi carbonate, creatinine, 
globulin, glucose, phosphorus, potassium, sodium, to tal bilirubin, total choles terol, total protein, 
triglycerides, magnesium, and uric acid.
Hematology tests include hemato crit, hemoglobin, platelet count , red blood cell (RBC) count, and 
white blood cell (WBC) count with differen tials (neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils).
11.1.8. Pregnancy
In the event that a female subject becomes preg nant following administration of ALD403 or may 
have been pregnant at the time of ALD403 exposure, or the partner of a male subject becomes 
pregnant following ALD403 administration to the male subject, the pregnancy must be reported 
to Alder within five business days of the In vestigator becoming aware of the pregnancy.  
Pregnancy information will be reported to Alder using the Exposure In-Utero Forms in EDC.  An 
Exposure In-Utero Notification Form should be used to report a pregnancy that occurs within [ADDRESS_385869] or congenital anomaly or hospi[INVESTIGATOR_313393].  
Every attempt should be made to follow a pregnancy to conclusion.  
Follow-up information is to be collected by [CONTACT_313420]:
xThe course of the pregnancy including perinatal and neonatal outcome, premature
termination of the pregnancy, or miscarriage 
xOffspring information including birth weight and birth defects (if any) 
11.1.9. Suicidal Ideation and Behavior 
Recent meta-analyses, spontaneous reports, a nd published case reports regarding suicidal 
ideation and behavior arising from drugs tested in clinical trials have been noted as an area of 
general concern. Based on this  information, the [LOCATION_002] Food and Drug Administration 
(FDA) has provided guidance to prospectively assess suicidal ideation and behavior in clinical 
trials to ensure that subjects in clinical trials who are experiencing suicidal ideation and behavior 
are properly recognized and adequately treated and to ensure the collection of more timely and 
more complete data on suicidal ideation and behavior than have  been collected in the past.12The 
C-SSRS (Columbia-Suicide Severity Rating Scale) will be used for this purpose.  Any subject who answers ‚Äúyes‚Äù to questions [ADDRESS_385870] who answers ‚Äúyes‚Äù to questions 4 or 5 in the Suicidal Ideation section or answers ‚Äúyes‚Äù 
to any question in the Suicidal Behavior sec tion of the C-SSRS will be discontinued from the 
study treatment as specified in Section 8.4.1, and re ferred by [CONTACT_298909] a mental health 
specialist.  Affirmative answers to questions [ADDRESS_385871] amine, serum tryptase, immunogl obulin E, and complement 
components.
Whether maintained in a ‚Äúformal crash cart‚Äù or separately, the following is a requirement at the 
site:
xCPR certification by [CONTACT_313421] (AED)
xEmergency medications including antihistamines, bronchodilators, IV saline, 
corticosteroids, acetaminophen, and epi[INVESTIGATOR_313394].
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 48of 7812. ASSESSMENT OF QUESTIONNAIRES, PK, AND 
IMMUNOGENICITY 
12.1. Questionnaires
Patient Global Impression of Change (PGIC)
The PGIC includes a single question concerning the subject‚Äôs impression of the change in their 
disease status since the start of the study. Se ven responses are possible: Very Much Improved, 
Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse, Very Much 
Worse.
SF-36 Health Survey (SF-36 v2.0)
The SF-[ADDRESS_385872] 4 weeks.  See Appendix 15.4.  The eight sections measured 
are vitality, physical functioning, bodily pai n, general health perceptions, physical role 
functioning, emotional role f unctioning, social role functi oning, and mental health.  
EQ-5D-5L
The EQ-5D-5L is a descriptive system of health -related quality of life stat es consisting of five 
dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) 
each of which can take one of five responses. The responses record five levels of severity (no 
problems/slight problems/modera te problems/severe problems/extreme problems) within a 
particular EQ-5D dimension. The EQ-5D-5L add itionally includes a VAS scale.  Each item will 
be summarized separately.
Headache Impact Test  (HIT-6 v1.0)
The Headache Impact Test (HIT) is a tool used to measure the impact and effect on the ability to 
function normally in daily life when a headache occurs. The HIT is a 6 question, Likert-type, 
self-reporting questionnaire with responses ra nging from ‚ÄúNever‚Äù to ‚ÄúAlways‚Äù with the 
following response scores: Never=6, Rarely= 8, Sometimes=10, Very Of ten=11, Always=13. See 
Appendix 15.3. The total score for the HIT is the sum of each response score and will be treated 
Protocol ALD403-CLIN-[ADDRESS_385873]:
Score Range Life Impact
>= 60
56-5950-55<= 49SevereSubstantialSomeLittle to None
Most Bothersome Symptom (MBS)
At screening, subjects will identify migraine related symptom that is most bothersome for them.  
Subjects will be asked to rate the improvement in this symptom from screening on a seven-point 
scale identical to the scale used for the PGIC.
The Migraine Disability Assessment (MIDAS)
The MIDAS questionnaire measur es the effect headaches have on the subject‚Äôs daily 
functioning.  Midas is composed of five questions that ask about  the subject‚Äôs performance over 
the past 3 months.  The response to each question is provided in number of days which are 
totaled to determine the level of disability: 0- 5, MIDAS Grade I, Little or no disability; 6-10,
MIDAS Grade II, Mild disability; 11-20, MIDAS Grade III, Moderate disability; 21+, MIDAS 
Grade IV, Severe disability.
12.2. Pharmacokinetics
The concentrations of ALD403 will be measured  in plasma from all treated subjects using a 
validated assay. The PK analysis will include ev aluations of concentrati on-time profiles for free 
ALD403 on Day 0 (pre-dose and immediately post-dos e (within 15 minutes of end of infusion), 
and Weeks 2, 4, 8, 12 (pre-dose), 24 (pre-dose), 36  (pre-dose), 48 (pre-dose), 72 (pre-dose), and 
104 or ET. 
All plasma PK samples will be stored at -20¬∞C or below prior to shippi[INVESTIGATOR_313395].Additional sample handling, processing, storage, labeling, and shippi[INVESTIGATOR_169019] a laboratory manual.
Protocol ALD403-CLIN-[ADDRESS_385874] blood 
samples to analyse for free ALD403 unless consent has been withdrawn.
12.3. Immunogenicity
Serum blood samples will be taken on Day 0 (pre-dose), a nd Weeks 2, 4, 8, 12 (pre-dose), 
24 (pre-dose), 36 (pre-dose), 48 (pre-dose), 72 (pre-dose) and [ADDRESS_385875] ALD 403 unless consent has been withdrawn. For any 
samples that are positive for anti-ALD403 anti body, there may be additional testing to 
characterize the anti-ALD403 antibody for the po tential to neutralize (NAb) ALD403 activity.  
Subjects who test positive for specific anti-ALD403 antibodies at the time of the last study visit 
will be asked to provide up to 2 additional blood samples for immunogenicity testing at 
approximately 3 month intervals for up to 6 months.
Additional sample handling, processing, storage, labeling, and shippi[INVESTIGATOR_169019] a laboratory manual. 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 51of 7813. STATISTICAL CONSIDERATIONS
13.1. Sample Size
The planned sample size for the study is 120 treat ed subjects.  It is assumed that over 75% of 
these subjects will complete the primary treatment phase resulting in at least [ADDRESS_385876] occurred on or after 
the intake of ALD403, except if an incomplete da te (e.g., month and year) clearly indicates that 
the event started prior to treatment. 
13.2.3. Populations to be Analyzed
The Safety Population, the analysis population for this study, includes all subjects who received 
at least one dose of treatment. 
13.3. Interim Analyses
This study will include a formal interim analysis after all subjects have completed the primary 
treatment phase. 
13.4. Statistical Methods
Continuous variables will be su mmarized with mean, median, standard de viation, minimum, and 
maximum. Categorical variables will be summarized with frequency and percentage. Change from baseline will be summarized as well as the results at the time point. 
Protocol ALD403-CLIN-[ADDRESS_385877] received trial drug ALD403. Demographic, baseline 
characteristics, migraine history and concomitant medications (coded by [CONTACT_169054]) will be summarized descriptively.
13.4.2. Efficacy Analyses
The Secondary endpoints will be su mmarized with descriptive sta tistics by [CONTACT_7206].  These 
summary measures will be base d upon the observed results and where appropriate the change 
from baseline results. Testing of these change from baseline results for the SF-36, MIDAS and 
HIT-[ADDRESS_385878]. 
13.4.3. Pharmacokinetic Analyses
Analysis of Drug Concentrations
The concentrations of ALD403 will be listed and su mmarized by [CONTACT_313422], and 
descriptive statistics will be provided. In this analysis, concentrations below the lower limit of 
quantification (LLOQ) will be set to zero.  
Plots of the individual concentrations of ALD 403 will be presented over  time (linear and log 
scales). Plots of the mean or median concentration will be presented over time (linear and log 
scales). When the scale is linear, concentrations below the lower limit of quantification will be 
set to zero. In the log-scaled figures, concentrations below the LLOQ will be imputed as 
LLOQ/2.  Population pharmacokinetic analysis will be performed on the results for ALD403 
concentrations obtained during this study in comb ination with the results from other studies of 
ALD403 in normal subjects  and migraine patients. 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 53of 7813.4.4. Safety Analyses
[IP_ADDRESS]. Adverse Events
The incidence of all AEs will be tabulated. These AEs will be classified by [CONTACT_313423] (MedDRA). For 
incidence reporting, if a subject reported more th an 1 AE that was coded to the same preferred 
term/system organ class, the s ubject will be counted only once for that specific preferred 
term/system organ class. Events recorded between the time the informed consent is signed and 
the first treatment administration will be listed.
An overview of AEs, which includes subject incide nce of AEs, SAEs, deaths, and AEs leading to 
discontinuation, will be presented. For AEs presente d by [CONTACT_926], the worst severity during the 
clinical trial will be presented for each subject.
The subject incidence of AEs will be summarize d by [CONTACT_6657].
[IP_ADDRESS]. Serious Ad verse Events
All SAEs will be listed and summarized in a similar manner to AEs. 
[IP_ADDRESS]. Clinical Laboratory Results
Summary statistics for actual values and for changes from baseline will be tabulated for clinical 
laboratory results by [CONTACT_96013]. Subjects with clinical laboratory values outside of the 
normal reference range at any post-baseline assessment will be summarized. Shifts from baseline 
clinical laboratory values base d upon the normal range will be tabulated. Subjects developi[INVESTIGATOR_313396].
[IP_ADDRESS]. Electrocardiogram (ECG) Results
The observed data at baseline and change from baseline for each measurement day will be 
summarized with descriptive statistics.  
[IP_ADDRESS]. Vital Signs
The observed data at baseline and change from  baseline for each measurement day will be 
summarized with descriptive statistics. 
Protocol ALD403-CLIN-[ADDRESS_385879] baseline.  Results for individual time points will be provided in a listing.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 55of 7814. ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS
14.1. Data Quality Assurance
Alder, or Alder‚Äôs designee will assess each site to verify the qualifications of the Investigator, 
according to Alder‚Äôs, or designee‚Äôs SOPs. Site facilities will be inspecte d, and the Investigator 
will be informed of responsibilities and the pro cedures for ensuring adequate and correct 
documentation.
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the clinical trial for each clinical 
trial subject. All information recorded on the CRFs for this clinical trial must be consistent with 
the subjects‚Äô source documentation (i.e., medical records).
14.2. Case Report Forms and Source Documents 
As part of the responsibilities assume d by [CONTACT_6231],  the principal investigator [INVESTIGATOR_119251]-investigator agrees to mainta in adequate case histories for the patients treated as part of the 
research under this protocol. The principal investigator [INVESTIGATOR_11637]-i nvestigator agrees to maintain 
accurate eCRFs and source documentation as part of the case histories. These source documents 
include, but are not limited to, laboratory reports and original ECGs. 
14.2.1. Study Documentation
Source document is defined as any hand written or  computer generated document that contains 
medical information or test results that have been  collected for or are in support of the protocol 
specifications, e.g., clinical laboratory reports, clin ic notes, drug disbursement log, subject sign 
in sheets, subject completed questionnaires if a pplicable, telephone logs, ECGs, etc. All draft, 
preliminary and pre-final iterations of a final report are also considered to be source documents, 
e.g., faxed laboratory reports and hard copy laboratory reports, faxed initial results and hard 
copy, final report.
14.2.2. Case Report Form 
The data collected during the study (except clinical laboratory test results, ECG results, PK 
analyses, Immunogenicity) will be recorded in the subject‚Äôs eCRF. The Short-Form Health 
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 56of 78Survey (SF-36), Health related Quality of Life  (EQ-5D-5L), Headache Impact Test (HIT-6), 
Patient Global Impression of Ch ange (PGIC), Most Botherso me Symptom (MBS) and C-SSRS 
will be completed on paper forms and then entered into the EDC system. The study site(s) will 
use an electronic data capture (EDC) system that is compliant with relevant Food and Drug 
Administration (FDA) regulatory requirements per [ADDRESS_385880]. However, 
these documents should be retained for a long er period if required by [CONTACT_169057]. 
It is the responsibility of the Investigator and clin ical trial staff to main tain a comprehensive and 
centralized filing system of all clinical trial-relate d documentation. This cen tralized file should 
be available for inspection at any time by [CONTACT_313424]. Elements of clin ical trial documentation should 
include:
xSubject files containing the completed CRF-supporting source documentation and the 
signed ICF
xClinical trial files, containing the protoc ol with all amendments, the Investigator 
Brochure, copi[INVESTIGATOR_313397], a nd all correspondence to and 
from the ethics committee and Alder Inc.
xPharmacy files, containing the Investigational Product Acc ountability Records or 
dispensation logs and all clinical  trial agent-related correspondence
Protocol ALD403-CLIN-[ADDRESS_385881] (or his/her legally authorized represen tative) according to the regulatory and legal 
requirements of the participating country. The consent forms must be dated and retained by [CONTACT_313425]. The Investigator will not undertake any 
investigation specifically required for the clinical trial until valid consent has been obtained. The terms of the consent and when it was obtained must also be documented in the CRF. Each 
subject will receive a fully-signed copy of each co nsent form that he/she signs for the clinical 
trial.
If a protocol amendment is required, the ICF may n eed to be revised to reflect the changes to the 
protocol. If the consent form is revised, it must  be reviewed and appr oved by [CONTACT_169060], and signed by [CONTACT_313426]. If  a male subject‚Äôs partner becomes pregnant during 
the subject‚Äôs participation in the trial, the partner will be asked to sign a separate pregnancy informed consent form to follow the pregnancy outcome, any complications, and the health of 
the baby.  The pregnancy consent should be obtai ned at the time the Investigator becomes aware 
of the pregnancy.
14.6. Protocol Approval and Amendment
Before the start of the clinical trial, the clini cal trial protocol and/or other relevant documents 
will be approved by [CONTACT_107650], in accordance with local legal requirements. Alder must ensure that all ethical and legal requireme nts have been met before the first subject is 
screened in the clinical trial.
The procedures outlined in the protocol and eCRFs will be carefully reviewed by [CONTACT_313427] l initiation to ensure appropriate interpretation and implementation. 
Protocol ALD403-CLIN-[ADDRESS_385882] be received from the appropriate  personnel and from the ethics committee before 
implementation (if appropriate). Amendments will originate from Alder and will be provided to the Investigator for submission to his/her ethics committee for their review and approval prior to 
implementation (if appropriate). It should be noted that when an amendment to a protocol 
substantially alters the clinical trial design or increases potential risk to the clinical trial subject, the ICF should be revised and, if applicable, subject ‚Äôs consent to continue participation should be 
obtained.
Administrative changes may be made without the need for a formal amen dment. All amendments 
will be distributed to all protocol recipi[INVESTIGATOR_840], with appropriate instructions.
14.6.1. Premature Termination of the Clinical Trial
Alder reserves the right to terminate this clinical trial at any time. The FDA or other governing 
national authority may also terminate the clinical trial.
The Investigator may discontinue pa rticipation in the trial. If the clinical trial is terminated prior 
to scheduled completion, the Investigator will be notified and given any necessary instructions 
concerning final examinations that are require d. If the Investigator, Alder, or the Medical 
Monitor becomes aware of conditions or events th at suggest a possible hazard to subjects if the 
clinical trial continues, the clinical trial may be  terminated after appropr iate consultation between 
the relevant parties. 
14.7. Confidentiality
All clinical trial findings and documents will be regarded as confidential. The Investigator and 
members of his/her research team must not di sclose such information without prior written 
approval from Alder.
The anonymity of participating subjects must be maintained. Subjects will be identified on CRFs 
and other documents by [CONTACT_2030] s ubject number and year of birt h date, not by [CONTACT_313428]403-CLIN-[ADDRESS_385883] (e.g., the signed 
informed consent) must be maintained in confidence by [CONTACT_737]. 
14.8. Publication Policy
By [CONTACT_169063], the Investigat or agrees with the use of results of the clinical 
trial for the purposes of nationa l and international registration, publication, and information for 
medical and pharmaceutical professionals. If ne cessary, the authorities will be notified of the 
Investigator's name, address, qualifications, and extent of involvement.
An Investigator shall not publish an y data (poster, abstract, paper,  etc.) without having consulted 
with Alder in advance. The information provided in support of or generated as a result of this 
clinical trial is confidential. Any use or reproduction thereof, including but not limited to 
publications or presentations by [CONTACT_21438]/her associates, must be submitted to Alder for review and approval in accordance with the provisions contained in the clinical trial agreement. All publications must ac knowledge the sponsorship of Alder.
All information not previously published concer ning ALD403 and Alder operations, including 
but not limited to patent applications, formulas, manufacturing processes, basic scientific data, 
and formulation information, supplied by [CONTACT_313429]. The Investigator agrees to use and maintain the confidentiality of this information in accordance with the provisions contained in the clinical trial 
agreement.
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 60of 7815. APPENDICES
15.1. Migraine preventive therapi[INVESTIGATOR_313380] 13, 
14, 15
xDivalproex sodium
xValproic Acid
xTopi[INVESTIGATOR_313398]*
xNaratriptan*
xZolmitriptan*
*only considered as prophylaxis when sp ecifically, used for menstrually-related 
migraine (MRM)
Other drugs for prophylaxis will be considered on a case by [CONTACT_413].
Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 61of 7815.2. Columbia-Suicide Severity Rating Scale (C-SSRS) Risk Assessment
15.2.1. Baseline/Screening Version

Protocol ALD403-CLIN-[ADDRESS_385884] (HIT-6 v1.0)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 68of 7815.4. Short-Form Health Survey (SF-36 v2.0)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 69of 78

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 70of 78

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 71of 78

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 72of 7815.5. Health Related Quality of Life (EQ-5D-5L)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 73of 78

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 74of 78

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 75of 7815.6. Patient Global Impression of Change (PGIC)
 g
Protocol ALD403-CLIN-[ADDRESS_385885] Bothersome Symptom (MBS)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 77of 7815.8. The Migraine Disability Assessment (MIDAS)

Protocol ALD403-CLIN-013
Alder BioPharmaceuticals, Inc.
16 January 2018
Version No. PR-0005.03 CONFIDENTIAL Page 78of 7815.9. References
1. Lipton R, Bigal M, Diamond M, Freitag F, Reed M, Stewart W. Migraine prevalence, 
disease burden, and the need for prev entive therapy. Neurology. 2007; 68:343-349.
2. Leonardi M, Steiner TJ, Scher AT, Lipton RB . The global burden of migraine: measuring 
disability in headache disorders with WHO‚Äôs classification of functioning, disability and 
health (ICF). J Headache Pain. 2005; 6(6):429-440.
3. Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health 
conditions in the [LOCATION_002]: results fro m the American Productivity Audit J Occup 
Environ Med 2003; 45(12): 1234-1246.
4. Headache Classification Committee of the International Headache Society. The 
International Classification of Headache Disorders, 3rdedition (beta version). 
Cephalalgia. 2013:33(9):629-808.
5. Katsarava, Buse D. Defining differences between epi[INVESTIGATOR_33176]. Curr 
Pain and Headache. 2012; 1:86-92.
6. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and 
comorbidity profiles of chronic migraine a nd epi[INVESTIGATOR_313399]. J Neurol 
Neurosurg Psychiatry. 2010; 81 (4):428-432.
7. Durham PL. CGRP-receptor antagonists‚Äîa fresh  approach to migraine therapy? N Engl 
J Med. 2004; 350:1073-1075.
8. Cady RJ, Shade CL, Cady RK. Advances in drug development for acute migraine. Drugs. 
2012:72(17):1-19.
9. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006; 
46(Suppl 1):S3-S8.
10. Hansen JM, Hauge AW, Olesen J, Ashina M.  Calcitonin gene-related peptide triggers 
migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010; 30(10):1179-1186.
11. Schmid CW, Konrad M, Schmid DM, et al . Prevalence of medication overuse headache 
in an interdisciplinary pain clinic. Journal of Headache and Pain 2013; 14:4.
12. [LOCATION_002] Food and Drug Administration, [LOCATION_002] Departme nt of Health and 
Human Services. Guidance for Industry: Suic idal Ideation and Behavior: Prospective 
Assessment of Occurrence in Clinical Trials, Draft Guidance. August 2012. Revision 1. 
13. Esternalik E, Tepper S.  Preventive treatment in migraine and the new US guidelines.  
Neuropsychiatr Dis Treat. 2013; 9; 709-720.
14. Antonaci F, Dumitrache C, De Cillis I, Allena M.  A review of current European 
treatment guidelines for migraine.  J Headache Pain.  2010; 11: 13-19.
15. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society Guideline for 
Migraine Prophylaxis - Section II.  Ca n J Neurol Sci 2012; 39: Suppl. 2 ‚Äì S8-28.